Physician profile
Debra Griner
NPI 1861460289
$9,130.01
in general payments reported to CMS, 2019-2025
69 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,185 · 2022: $1,608 · 2023: $2,245 · 2024: $1,923 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,927 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,927.29 |
| Education | $409.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $702.09 | 2021-2025 | |
| Pfizer INC. | $644.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $622.77 | 2021-2025 | Imfinzi, Lynparza, Enhertu |
| Janssen Biotech, INC. | $582.46 | 2022-2025 | Tecvayli, Rybrevant, Talvey |
| Incyte Corporation | $474.25 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Merck Sharp & Dohme LLC | $405.29 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $370.79 | 2021-2024 | Padcev, Adcetris, Tukysa |
| Amgen INC. | $350.55 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Abbvie INC. | $334.32 | 2023-2025 | |
| Exelixis INC. | $309.81 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $288.60 | 2022-2025 | Vyloy, Padcev |
| Genzyme Corporation | $273.80 | 2021-2025 | |
| Daiichi Sankyo INC. | $192.97 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Sumitomo Pharma America, INC. | $191.19 | 2023-2025 | Orgovyx |
| Sanofi-Aventis U.S. LLC | $178.00 | 2021-2023 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $162.72 | 2022-2025 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $154.27 | 2023-2025 | Opdivo, Krazati |
| Regeneron Healthcare Solutions, INC. | $153.09 | 2022-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $147.47 | 2022-2025 | Fotivda |
| Gilead Sciences, INC. | $138.24 | 2021-2025 | Trodelvy |
| Myovant Sciences INC. | $131.17 | 2021-2022 | |
| Eisai INC. | $119.98 | 2021-2025 | |
| Celgene Corporation | $118.64 | 2022-2024 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $117.17 | 2021-2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $112.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.76 | 2022-2024 | Entyvio, Ninlaro, Vonvendi |
| Sobi, INC | $111.56 | 2022-2025 | |
| Genentech USA, INC. | $91.07 | 2023-2025 | Venclexta, Tecentriq Hybreza, Ocrevus |
| Lilly USA, LLC | $88.96 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $76.93 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Legend Biotech USA INC. | $73.38 | 2024-2025 | Carvykti |
| Array Biopharma INC | $61.55 | 2025 | Braftovi, Mektovi, Tukysa |
| Dendreon Pharmaceuticals LLC | $61.11 | 2024-2025 | Provenge |
| Beigene USA, INC. | $58.95 | 2023-2024 | Brukinsa |
| Fresenius Kabi USA, LLC | $58.94 | 2023-2024 | Stimufend |
| Emd Serono, INC. | $56.06 | 2021-2023 | Bavencio |
| Tersera Therapeutics LLC | $55.16 | 2021-2025 | Xermelo |
| Mirati Therapeutics, INC. | $54.78 | 2023-2024 | Krazati |
| Coherus Oncology, INC. | $53.66 | 2023-2024 | |
| Puma Biotechnology, INC. | $52.11 | 2023-2025 | |
| Kite Pharma, INC. | $49.79 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $46.97 | 2021-2023 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $44.60 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $44.14 | 2021-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $43.99 | 2021-2023 | Ultomiris |
| Spectrum Pharmaceuticals INC. | $40.28 | 2023 | Rolvedon |
| Cti Biopharma Corp. | $38.47 | 2023 | Vonjo |
| Kyowa Kirin, INC. | $35.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.61 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $33.25 | 2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $30.52 | 2021-2023 | Qinlock |
| Blueprint Medicines Corporation | $28.87 | 2024 | Ayvakit |
| Taiho Oncology, INC. | $25.44 | 2021 | |
| Heron Therapeutics, INC. | $24.27 | 2021 | |
| Celltrion USA INC. | $23.04 | 2025 | Vegzelma |
| Caris Mpi, INC. | $22.93 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $22.20 | 2023 | Orserdu |
| Avyxa Pharma, LLC | $21.95 | 2024 | |
| Novocure INC. | $21.04 | 2022 | |
| Accord Healthcare, INC. | $20.06 | 2025 | |
| Pharming Healthcare, INC. | $19.72 | 2023 | Ruconest |
| Epizyme, INC. | $17.29 | 2021 | |
| Pharmaessentia USA Corporation | $15.63 | 2023 | Besremi |
| Organon LLC | $14.72 | 2023 | Ontruzant |
| X4 Pharmaceuticals, INC. | $14.29 | 2024 | Xolremdi |
| Myriad Genetic Laboratories, INC. | $13.96 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $13.86 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $13.23 | 2023 | Akynzeo |
| Chiesi USA, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
Orgovyx $377Keytruda $322Cabometyx $310Imbruvica $227Epkinly $227Xtandi $197Tecvayli $195Rybrevant $190Adcetris $182Elrexfio $176Padcev $171Carvykti $160Talvey $153Darzalex $153Kisqali $152Monjuvi $149Talzenna $143Ibrance $133Enhertu $132Onivyde $130Sarclisa $130Opdivo $122Lynparza $117Fotivda $116Imfinzi $111Venclexta $108Jevtana $106Lenvima $105Libtayo $99.09Comirnaty $96.86Jakafi $96.48Nubeqa $95.48Xofigo $95.48Pemazyre $92.26Tukysa $90.26Bosulif $89.64Besponsa $89.64Krazati $87.04Vonjo $79.67Lutathera $78.12Welireg $71.13Pluvicto $70.77Lupron Depot $70.12Reblozyl $66.81Mektovi $61.55Braftovi $61.55Provenge $61.11Scemblix $59.57Erleada $59.40Brukinsa $58.95Stimufend $58.94Fabhalta $57.16Jaypirca $57.13Verzenio $57.13Entyvio $53.80Udenyca $53.66Trodelvy $51.82Xgeva $45.67Nplate $45.67Vectibix $45.67Vyloy $44.30Xermelo $40.91Rolvedon $40.28Nerlynx $38.65Akeega $38.34Doptelet $35.04Monoferric $33.25Paxlovid $31.86Zejula $30.27Jemperli $30.27Tecentriq Hybreza $29.94Promacta $29.90Xpovio $28.89Ayvakit $28.87Bavencio $28.43Tasigna $28.06Lorbrena $27.53Akynzeo $26.46Somatuline Depot $26.39Ninlaro $25.84Vegzelma $23.04Mi Cancer Seek $22.93Keytruda Qlex $22.23Orserdu $22.20Posfrea $21.95Docivyx $21.95Cyclophosphamide $21.95Balversa $20.78Camcevi $20.06Ultomiris $19.90Ruconest $19.72Poteligeo $18.72Ocrevus $16.61Ojjaara $16.01Besremi $15.63Injectafer $15.37Vonvendi $15.24Retevmo $14.90Kyprolis $14.82Blincyto $14.82
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Griner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.